Publications

Spinner MA, Advani RH. Management of Classic Hodgkin Lymphoma in Pregnancy. Hematology/oncology clinics of North America. 2026. PMID: 41654459

Lopez CM, Suarez JF, Mendoza MA, Anderson AD, Lykon J, Li W, Morris MI, Natori Y, Raja M, Lekakis LJ, Beitinjaneh A, Jimenez A, Goodman M, Wang TP, Spiegel J, Holtzman NG, Pereira D, Green D, Komanduri KV, Camargo JF. Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary Era. Mycopathologia. 2026. PMID: 41642400

Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu KS, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Odstrcil Bobillo S, Hilal T, Park JH, Valtis YK, Faramand RG, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine JP, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran M, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock WA, Schwartz MS, Byrd K, Yalniz FF, Bachanova V, Tracy SI, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai C, Muffly LS. Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene. Blood. 2026. PMID: 41643192

Zeidner JF, Jain J, Welkie RL, Huang Y, Swords R, Traer E, Stein EM, Lin TL, Madanat YF, Collins RH, Baer MR, Duong VH, Blum W, Arellano ML, Stock WA, Odenike O, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran E, Handa S, Heerema NA, Chen TL, Martycz M, Stefanos M, Marcus S, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Mims AS, Byrd JC, Borate UM. Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report. Blood advances. 2026. PMID: 41632633

Han Y, Byun J, VanLith CJ, Cooley MA, Shaw VR, Hatia RI, Ahmed FY, Giama NH, Ali HM, Campbell NA, Hassan M, Andersen JB, Ankoma-Sey V, Banales JM, Bujanda L, Bathe OF, Bekaii-Saab TS, Borad MJ, Björkström NK, Chan CHF, Cleary SP, Cornillet M, Folseraas T, Galle PR, Genkinger JM, MacInnis RJ, Gores GJ, Goyal L, Houlston RS, Ilyas SI, Javle M, Johansen JS, Christensen TD, Kamath AS, Kelley RK, Khan SA, Kim RD, Kwee SA, Lamarca A, Lammert F, LaRusso NF, Lindsey S, Macias RIR, Malhi H, Patel TC, Permuth JB, Reeves HL, Rossi S, Sanchez W, Smoot RL, Swerdlow AJ, Tran Cao HS, Valle JW, Weinmann A, Weinmann-Menke J, Wong LL, Zhang X, Zimmer V, Zhu AX, Lazaridis KN, Juran BD, Jalal P, Knox JJ, Hutchinson A, Hicks B, Koshiol JE, Chanock SJ, Hassan MM, Amos CI, McGlynn KA, Roberts LR. Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. Hepatology (Baltimore, Md.). 2026. PMID: 41627892

Advani RH, Kelsey CR, Armand P, Bello CM, Benitez CM, Bond D, Chen W, Cherian S, Czader M, Dabaja B, Daly ME, Frosch Z, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Hoppe RT, Isufi I, Johnston PB, Kelly K, Kenkre VP, Kline J, Lynch RC, McConathy J, Morgan D, Niu A, Paul S, Rabinovitch R, Salavati A, Sano D, Shah H, Spinner M, Svoboda J, Winter JN, Yahalom J, Yang JC, Montgomery S, Stehman K. Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41671432

Ma S, Spinner MA. Optimizing the Role of Checkpoint Inhibitors in the Management of Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41698326

O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. Journal for immunotherapy of cancer. 2026. PMID: 41617393

Jhaveri KL, Iyengar NM, Turner NC, Rugo HS, O'Shaughnessy J, Barrios CH, Curigliano G, André F, Im SA, Goncalves MD, Lacouture ME, Fasching PA, Leung R. Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer. ESMO open. 2026. PMID: 41604817

Foisey MG, Garcia J, Li X, Yang X, Hilburger C, Thienpont C, Chaves-Martinez A, Belkaya S, Truong T, Zhu I, Liu R, Hyrenius-Wittsten A, Almeida R, Shy BR, Allen GM, Wyman S, Roybal KT. Synthetic Hybrid Receptors for Safer and Programmable T Cell Therapy. bioRxiv : the preprint server for biology. 2026. PMID: 41648153

Luck C, Luo Y, Vasileva E, Jacobs KA, Riad J, Macaraig CD, Ponce RKM, Amatruda JF, Okimoto RA. Modeling of Capicua Family Fusion Oncoprotein-Driven Cancers Reveals Gene-Specific Functionality. Molecular cancer research : MCR. 2026. PMID: 41575738

Martin TG, van de Donk NWCJ, Rodríguez-Otero P, Mateos MV, Kobos R, Chastain K, Doyle M, Nooka AK. Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma. Future oncology (London, England). 2026. PMID: 41574880

Bidkar AP, Bidlingmaier S, Wadhwa A, Mayne E, Raveendran A, Naik S, Xue C, Basak M, Bobba KN, Patiño-Escobar B, Greenland N, Camara Serrano JA, Steri V, Chou J, Wiita A, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41569419

Herasymenko O, Silva M, Correy GJ, Abu-Saleh AAA, Ackloo S, Arrowsmith C, Ashworth A, Ban F, Beck H, Bishop KP, Bohórquez HJ, Bolotokova A, Breznik M, Chau I, Chen Y, Cherkasov A, Dehaen W, Della Corte D, Denzinger K, Doering NP, Edfeldt K, Edwards A, Fayne D, Gentile F, Gibson E, Gokdemir O, Gunnarsson A, Günther J, Irwin JJ, Jensen JH, Harding RJ, Hillisch A, Hoffer L, Hogner A, Hutchinson A, Kandwal S, Karlova A, Koirala K, Kotelnikov S, Kozakov D, Lee J, Lee S, Lessel U, Liu S, Liu X, Loppnau P, Meiler J, Moretti R, Moroz YS, Muvva C, Oprea TI, Paige B, Pandit A, Park K, Poda G, Protopopov MV, Pütter V, Ravichandran R, Rognan D, Rosta E, Sabnis Y, Scott T, Seitova A, Sharma P, Sindt F, Song M, Steinmann C, Stevens R, Talagayev V, Tararina VV, Tarkhanova O, Tingey D, Trant JF, Treleaven D, Tropsha A, Walters P, Wells J, Westermaier Y, Wolber G, Wortmann L, Zheng S, Fraser JS, Schapira M. CACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2. Journal of chemical information and modeling. 2026. PMID: 41565251

Pan S, Fernández-Maestre I, Chang KC, Van Haver S, Wereski MG, Haugh AM, Tsai KK, Daud AI, Bowman RL, Vasudevan HN, Levine RL, Abate AR. PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells. Nature communications. 2026. PMID: 41565684

Li T, Ilano A, Arias-Badia M, Luong D, Chang H, Kwek SS, Allaire K, Chumber A, Sakamoto M, Clark M, Lea A, Bridge M, Chen B, Liu E, Porten S, Meng MV, Erlich LIR, Oh DY, Fong L. Functionally heterogeneous intratumoral CD4+CD8+ double-positive T cells can give rise to single-positive T cells. Proceedings of the National Academy of Sciences of the United States of America. 2026. PMID: 41557789

Tolaney SM, Sammons S, Sandoval-Leon A, Cortes J, Liepa AM, Grimes BR, He D, Cui ZL, Roose J, Gathirua-Mwangi W, Moreira K, O'Shaughnessy J, Neven P, Johnston SRD, Rugo HS. Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data. ESMO open. 2026. PMID: 41558202

Hertz DL, Venook AP. Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41632507

Tsui M, Hu K, Song H, Hsu SC, Chen YA, Nuniz L, Pham JH, Chang CH, Hui KSF, Quigley DA, Li J, Huang FW. Landscape of allele-specific expression in prostate cancer reveals recurrent, stage-specific events in AR signaling and resistance pathways. Molecular cancer research : MCR. 2026. PMID: 41543497

Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC. Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026. PMID: 41144772